DTaP vaccine adult - Baxter International

Drug Profile

DTaP vaccine adult - Baxter International

Alternative Names: Amvax

Latest Information Update: 09 Mar 2011

Price : $50

At a glance

  • Originator Baxter International
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diphtheria; Pertussis; Tetanus

Most Recent Events

  • 27 Jun 2000 North American Vaccine has been acquired by and merged into Baxter International
  • 31 Dec 1998 Phase-I clinical trials for Pertussis in USA (Unknown route)
  • 31 Dec 1998 Phase-I clinical trials for Diphtheria in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top